Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Winter Discusses Copanlisib in Follicular Lymphoma

November 18th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

MRD, Genetic Classification Provide More Accurate Risk Stratification in Pediatric ALL

November 17th 2017

Investigators working in the UK and Europe found a correlation between minimal residual disease kinetics and risk for relapse in pediatric patients with acute lymphoblastic leukemia.

FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma

November 17th 2017

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

FDA Approves Frontline Obinutuzumab for Follicular Lymphoma

November 16th 2017

The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma.

CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia

November 16th 2017

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

November 16th 2017

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.

Dr. Stone on Monitoring Patients With AML

November 15th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.

Brentuximab Vedotin Nears European Approval for CTCL

November 15th 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) in adults with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL

November 14th 2017

Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL.

Acalabrutinib Among Exciting Options Emerging in CLL

November 14th 2017

Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.

Dr. Mims Discusses Momelotinib in Myelofibrosis

November 10th 2017

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

November 10th 2017

The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

November 10th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

FDA Approves Brentuximab Vedotin for CTCL

November 10th 2017

The FDA has approved brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma who have received prior systemic therapy.

Refining Role of Brentuximab Vedotin and Immunotherapy in Hodgkin Lymphoma

November 9th 2017

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.

Better Outcomes in High-Risk Multiple Myeloma

November 9th 2017

Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.

FDA Approves Vemurafenib for Rare Blood Cancer

November 6th 2017

The FDA has approved vemurafenib as a treatment for patients with Erdheim-Chester disease.

R-CVP Associated with 83% 8-Year OS for Advanced Symptomatic Follicular Lymphoma

November 3rd 2017

According to phase III results from the FOLL05 trial, the combination of rituximab plus cyclophosphamide, vincristine, and prednisone produced survival results comparable with standard-of-care regimens in patients with advanced symptomatic follicular lymphoma.

Personalized Medicine Moving to Forefront of Hematologic Malignancies

November 3rd 2017

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

FDA Approval Sought for Frontline Brentuximab Vedotin for Hodgkin Lymphoma

November 3rd 2017

A supplemental new drug application has been submitted for brentuximab vedotin in combination with Adriamycin, vinblastine, dacarbazine as a frontline treatment for advanced classical Hodgkin lymphoma.